H4ZL:F:F-HSBC FTSE EPRA NAREIT Developed UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 17.748

Change

+0.26 (+1.48)%

Market Cap

N/A

Volume

N/A

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-09 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
SXR8:F iShares Core S&P 500 UCITS ETF..

-10.97 (-2.15%)

USD 101.74B
UIM5:F UBS (Lux) Fund Solutions - MSC..

+0.96 (+2.02%)

USD 101.37B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

N/A

USD 96.03B
XDNY:F Xtrackers MSCI Japan ESG Scree..

+0.33 (+2.33%)

USD 57.02B
XJSE:F Xtrackers II - Japan Governmen..

N/A

USD 53.72B
VUSA:F Vanguard Funds Public Limited ..

N/A

USD 51.63B
SXRZ:F iShares VII PLC - iShares Nikk..

+0.25 (+0.12%)

USD 45.80B
0ZC:F Zscaler Inc

-1.28 (-0.71%)

USD 37.92B
BSND:F Danone SA

+0.20 (+1.42%)

USD 33.83B
VGWL:F Vanguard FTSE All-World UCITS ..

N/A

USD 24.77B

ETFs Containing H4ZL:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -11.20% 35% F 53% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -11.20% 35% F 52% F
Trailing 12 Months  
Capital Gain -5.40% 36% F 57% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -5.40% 33% F 49% F
Trailing 5 Years  
Capital Gain -2.61% 25% F 36% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -2.61% 25% F 23% F
Average Annual (5 Year Horizon)  
Capital Gain 2.72% 43% F 48% F
Dividend Return 2.72% 40% F 41% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 10.05% 67% D+ 91% A-
Risk Adjusted Return 27.06% 39% F 50% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.